Beyond Longevity: Is Urolithin A a Breakthrough Compound for a Healthier Brain?

Urolithin A is a "postbiotic", meaning a metabolite of polyphenols derived from the gut microbiome, specifically from sources such as pomegranates, berries, nuts, tea, and various fruits. Due to its specific molecular weight, this compound can cross the blood-brain barrier. Numerous studies focus on the mechanisms of action of Urolithin A, indicating that it may promote autophagy, thereby increasing resilience in neurodegenerative models.

It's not just the gut that's the problem…

Not everyone naturally produces Urolithin A. Only about 30–40% of people have the specific gut microbiome composition necessary to convert dietary precursors (ellagitannins and ellagic acid) into significant amounts of Urolithin A. This phenomenon introduces a clear division in the literature between "producers" vs. "non-producers". Even with a healthy diet, adults produce very little or no Urolithin A at all. The ability to produce Urolithin A may also decline with age, which justifies the scientific search for methods of direct supplementation.

Urolithin A as a support for overall health

In scientific literature and biochemical analyses, the following potential health benefits are most frequently studied and described:

Antioxidant activity: Urolithins possess strong antioxidant properties, which may help neutralise free radicals, providing cellular protection.

Anti-inflammatory effects: It may modulate inflammatory pathways, potentially alleviating chronic conditions such as arthritis and cardiovascular diseases.

Gut microbiome enhancement: It may promote beneficial gut bacteria, which are linked to improved metabolic health, digestion, and immune function.

Longevity and cellular health: It may improve mitochondrial function, cellular repair processes, and activate autophagy – key for maintaining cellular longevity, indicating a potential role in healthy ageing.

Antidepressant effects: Urolithin A has demonstrated the ability to inhibit monoamine oxidase A (MAO-A), which is responsible for breaking down neurotransmitters (such as serotonin and dopamine). This may contribute to mood stabilisation and support mitochondrial health.

Neuroprotective properties of Urolithin A

A 2026 study published in BMC Pharmacol Toxicol showed that both Urolithin A and B improved memory in rats with Alzheimer's-like pathology: reduced anxiety-like behaviour and lowered oxidative stress markers in the brain. Importantly, these compounds demonstrated the ability to reduce necrotic neurons and amyloid deposits in key brain regions, without causing toxicity in internal organs.

A 2023 study – Urolithin A and DYRK1A inhibition, published in the Journal of Food and Drug Analysis, yields the following conclusions:

• Urolithin A acts as a potent inhibitor of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), which is involved in Alzheimer's disease pathology, leading to beneficial changes in tau protein phosphorylation.
• Neuroprotective effects: In cellular models exposed to amyloid-beta (Aβ), Uro A inhibited the production of pro-inflammatory cytokines such as IL-6 and TNF-α, thereby reducing Aβ-induced neurotoxicity.
• Cognitive improvement: In a mouse model of Alzheimer's disease induced by okadaic acid, Uro A led to significant improvement in spatial learning and memory functions.

Urolithin A and neuroplasticity

A 2021 study – Urolithin A and synaptic plasticity – published in the Journal of Neuroscience Research contains key insights: Urolithin A was shown to increase synaptic plasticity in hippocampal neuron cultures and may promote long-term potentiation, a key mechanism involved in learning and memory.

A 2022 study – Anti-inflammatory properties of Urolithin A – published in Frontiers in Aging Neuroscience, highlighted its ability to reduce neuroinflammation markers in ageing neuronal cells, which correlates with improved cognitive performance in aged mice.

Molecular mechanism

Behind all these processes lies a highly advanced molecular mechanism:

• Activation of AMPK: UA activates AMP-activated protein kinase (AMPK), regulating cellular energy balance.
• Activation of CREB may lead to increased expression of brain-derived neurotrophic factor (BDNF).
• Increased BDNF expression may improve neurogenesis and synaptic functions, crucial for mood regulation.

Urolithin A is more potent, yet still quite similar in structure to Epicatechin (EGCG or Matcha) and Resveratrol. Given current scientific data, a dosage of 500–1000 mg for 8–12 weeks appears to be the best option for brain and cellular longevity.

References:

Urolithins: Promising nutritional interventions for mild cognitive impairment https://doi.org/10.1016/j.jff.2026.107243

Neuroprotective effects of Urolithin A and B in an intracerebroventricular streptozotocin-induced Alzheimer's-like model in rats PMC13081563

Pharmacological Effects of Urolithin A and Its Role in Muscle Health and Performance: Current Knowledge and Prospects PMC10609777

Urolithin A improves mitochondrial health, reduces cartilage degeneration, and alleviates pain in osteoarthritis https://doi.org/10.1111/acel.13662

Targeting aging with urolithin A in humans: A systematic review https://doi.org/10.1016/j.arr.2024.102406

Urolithin A improves Alzheimer's disease cognition and restores mitophagy and lysosomal functions PMC11180933

Urolithin A Abolishes High Anxiety and Rescues the Associated Mitochondria-Related Transcriptomic Signatures and Synaptic Function 10.1016/j.biopsych.2025.07.020